checkdown-arrowsearchshare

This site is intended for healthcare professionals outside the U.S.

The OTEZLA® International Website


close x

You are now leaving Otezla.net!


Gain a deeper understanding of psoriasis

Psoriasis is a systemic inflammatory disease

 

Gain insight into the prevalence of psoriasis, how it affects patients at a cellular level, and what phosphodiesterase 4 (PDE4) inhibition may mean for treatment


About Psoriasis

Inflammation is a tightly regulated, naturally occurring part of the body’s protective response to injury or infection, intended to prevent damage to surrounding tissue. In response to inflammation, several mechanisms work to regulate this immune response. Thus, these regulatory mechanisms help to establish immune homeostasis.1

The most common form of psoriasis, plaque psoriasis, manifests as well-demarcated, raised, scaly, erythematous skin lesions. These lesions can appear anywhere on the body but are most commonly found on the scalp, elbows, nails, lower back, and knees.2,3

Psoriasis plaque formation is thought to be caused by dysregulated immune activity within the skin. This dysregulation can lead to an imbalance and overproduction of pro-inflammatory cytokines such as TNF-α, IL-23, IL-17, and IFN-γ in immune cells.2,4,5

These cytokines promote chronic inflammation of the epidermis and induce keratinocyte hyperproliferation. These changes result in redness, itching, epidermal thickening, and scaly plaques.3-10

Where can I find more information and support?

Additional PDE4 resources

A video explanation of how OTEZLA affects multiple cytokines

DiscoverPDE4.com

Meetings and symposia

European Academy of Dermatology and Venereology (EADV)

American Academy of Dermatology (AAD)

Advocacy and education

National Psoriasis Foundation (NPF)

The European Umbrella Organization for Psoriasis Movements (EUROPSO)

The International Federation of Psoriasis Associations (IFPA)

References: 1. Van Parijs L et al. Science. 1998;280:243‑248. 2. Mason AR et al. Cochrane Database Syst Rev. 2013;3:CD005028. 3. National Psoriasis Foundation. An Overview of Psoriasis and Psoriatic Arthritis. Portland, OR: National Psoriasis Foundation; 2009. 4. Lowes MA et al. Nature. 2007;445(7130):866-873. 5. Nestle FO et al. N Engl J Med. 2009;361:496‑509. 6. Schön MP et al. N Engl J Med. 2005;352(18):1899-1912. 7. Perera GK et al. Annu Rev Pathol. 2012;7:385-422. 8. Balato A et al. Psoriasis. Rijeka, Croatia: InTech Europe; 2012. 9. Dogan S et al. Psoriasis—Types, Causes and Medication. Rijeka, Croatia: InTech Europe; 2013. 10. Menter A et al. J Am Acad Dermatol. 2011;65(1):137-174.


Select an e-mail client to share

close x